Insmed said on Tuesday it would discontinue the development of its treatment for a chronic, inflammatory skin condition, after the drug failed a mid-stage trial.
The drug, brensocatib, did not meet the main goal of reducing painful lumps in patients with hidradenitis suppurativa, the company said.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.